Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics
FULC Price/Volume Stats
| Current price | $7.06 | 52-week high | $13.70 |
| Prev. close | $7.15 | 52-week low | $2.43 |
| Day low | $6.90 | Volume | 526,200 |
| Day high | $7.21 | Avg. volume | 654,177 |
| 50-day MA | $9.49 | Dividend yield | N/A |
| 200-day MA | $6.05 | Market Cap | 437.26M |
FULC Stock Price Chart Interactive Chart >
Fulcrum Therapeutics, Inc. (FULC) Company Bio
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Latest FULC News From Around the Web
Below are the latest news stories about FULCRUM THERAPEUTICS INC that investors may wish to consider to help them evaluate FULC as an investment opportunity.
APP Stock Price Predictions: Is AppLovin Really Worth $50?Applovin (APP) stock is in the news Tuesday after the stock got a new price target from Jefferies analyst Andrew Uerkwitz. |
BLNK Stock Alert: Blink Charging Signs Deal to Bring EV Charging to McDonald’sBlink Charging (BLNK) stock is on the move Tuesday after the EV charging company signed a deal that brings its services to McDonald's (MCD). |
Why Is Fulcrum Therapeutics (FULC) Stock Up 43% Today?Fulcrum Therapeutics (FULC) stock is on the rise Tuesday after the FDA removed a clinical hold on its sickle-cell disease candidate. |
FULC Price Returns
| 1-mo | -30.10% |
| 3-mo | 2.02% |
| 6-mo | 93.96% |
| 1-year | 182.40% |
| 3-year | -37.74% |
| 5-year | N/A |
| YTD | 4.59% |
| 2023 | -7.28% |
| 2022 | -58.85% |
| 2021 | 51.07% |
| 2020 | -29.63% |
| 2019 | N/A |
Loading social stream, please wait...